JNCCN-360

Editors:

James L. Mohler, MD

Richard J. Lee, MD, PhD

Advertisement

Advertisement

Carmel Jo Pezaro, MB, ChB, on Prostate Cancer and PARP Inhibitors

James L. Mohler, MD, on Prostate Cancer: Management Approaches

Peter R. Carroll, MD, MPH, on Prostate Cancer: Risks of Early Detection

Recent

Prostate Cancer Research Funded by U.S. Department of Defense

Does Addition of Abiraterone to Enzalutamide Therapy Benefit Men With Prostate Cancer?

Prostate Cancer Foundation Funds 2018 Young Investigator Awards

Early Detection of Metastatic Prostate Cancer: Impact on Incidence and Survival

Published

Medical Literature

Low Free Testosterone Concentration May Equal Low Prostate Cancer Risk

Survival Impact of Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

Does Surgical Technique Affect Outcomes in Patients With Prostate Cancer?

New Prognostic Imaging Biomarker in Metastatic Prostate Cancer

Ongoing

Cases From the Community: Clinical Investigators Provide Their Perspectives on the Use of Immune Checkpoint Inhibitors in the Management of Actual Patients With Genitourinary Cancers

New Directions in Nonmetastatic CRPC: Perspectives on the Latest Data (login required)

Metastatic CRPC: Clinical Strategies (login required)

Prostate Cancer Patient Management Simulator

Available

Clinical Trials

University of Wisconsin Carbone Cancer Center

UC San Diego Health Moores Cancer Center

The Ohio State University Comprehensive Cancer Center

The Sidney Kimmel Comprehensive Cancer Center

Sections

NCCN Resources

Copyright © 2018 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.